Author/Authors :
Mukohara, Toru Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Sasaki, Akinori Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Harano, Kenichi Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Kogawa, Takahiro Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Matsubara, Nobuaki Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Naito, Yoichi Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Hosono, Ako Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Mukai, Hirofumi Department of Breast and Medical Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan , Yoshino, Takayuki Department of Gastroenterology and Gastrointestinal Oncology - National Cancer Center Hospital East - Kashiwa - Chiba, Japan
Abstract :
Intestinal perforation is a rare adverse event of antineoplastic therapy. However, once it occurs, it is potentially fatal. This reportdescribes a case of intestinal perforation caused by bevacizumab in a patient with ovarian cancer who concurrently developedneutropenic enterocolitis. A 66-year-old woman diagnosed with metastatic ovarian cancer received combination chemotherapywith carboplatin, gemcitabine, and bevacizumab. On day 14, she developed grade 4 pancytopenia and febrile neutropenia, whichresulted in neutropenic enterocolitis and intestinal perforation. Emergency surgery was performed, and an intestinal perforationfound in the ascending colon was closed. Postoperatively, she developed an intra-abdominal abscess requiring peritonealdrainage. She was discharged from the hospital on recovery.
Keywords :
Intestinal Perforation due , Neutropenic Enterocolitis , Patient Treated , Bevacizumab , Ovarian Cancer , VEGF
